- Home
- TXG vs GSBD Comparison
TXG vs GSBD Comparison
Compare TXG & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXG
- GSBD
- Stock Information
- Founded
- TXG 2012
- GSBD 2012
- Country
- TXG United States
- GSBD United States
- Employees
- TXG N/A
- GSBD N/A
- Industry
- TXG Biotechnology: Laboratory Analytical Instruments
- GSBD Finance: Consumer Services
- Sector
- TXG Industrials
- GSBD Finance
- Exchange
- TXG Nasdaq
- GSBD Nasdaq
- Market Cap
- TXG 1.5B
- GSBD 1.5B
- IPO Year
- TXG 2019
- GSBD N/A
- Fundamental
- Price
- TXG $10.90
- GSBD $13.20
- Analyst Decision
- TXG Buy
- GSBD Hold
- Analyst Count
- TXG 16
- GSBD 2
- Target Price
- TXG $20.36
- GSBD $13.00
- AVG Volume (30 Days)
- TXG 2.9M
- GSBD 796.5K
- Earning Date
- TXG 02-12-2025
- GSBD 02-27-2025
- Dividend Yield
- TXG N/A
- GSBD 13.64%
- EPS Growth
- TXG N/A
- GSBD N/A
- EPS
- TXG N/A
- GSBD 0.67
- Revenue
- TXG $610,785,000.00
- GSBD $445,944,000.00
- Revenue This Year
- TXG $4.38
- GSBD N/A
- Revenue Next Year
- TXG $9.08
- GSBD N/A
- P/E Ratio
- TXG N/A
- GSBD $19.62
- Revenue Growth
- TXG N/A
- GSBD N/A
- 52 Week Low
- TXG $10.80
- GSBD $11.72
- 52 Week High
- TXG $48.42
- GSBD $15.94
- Technical
- Relative Strength Index (RSI)
- TXG 24.63
- GSBD 63.86
- Support Level
- TXG $11.43
- GSBD $13.11
- Resistance Level
- TXG $13.12
- GSBD $13.45
- Average True Range (ATR)
- TXG 0.98
- GSBD 0.19
- MACD
- TXG -0.24
- GSBD 0.05
- Stochastic Oscillator
- TXG 2.27
- GSBD 73.22
About TXG 10x Genomics Inc.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
About GSBD Goldman Sachs BDC Inc.
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company's origination strategy focuses on leading the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.